Sol-Gel Technologies SLGL
NASDAQ SLGL
$69.96 -0.14 (-0.20%)
As of: Sep 4, 2026 · 3:59 PM EDT

Sol-Gel Technologies (SLGL) Receivables (2019 - 2026)

Sol-Gel Technologies (SLGL) posted quarterly Receivables of $1.1 million for Q1 2026, down 72.52% year-over-year from $3.9 million in Q1 2025, and down 45.78% quarter-over-quarter from $2.0 million in Q4 2025.

Analysis

Sol-Gel Technologies (SLGL) Receivables (2019 - 2026) Analysis & Trends

Sol-Gel Technologies (SLGL) has reported Receivables for 8 consecutive years, with $1.1 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Receivables fell 72.52% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $1.1 million (down 72.52% YoY), while the FY2025 annual figure was $2.0 million, down 45.26% from the prior year.
  • Receivables retreated to $1.1 million in Q1 2026 per SLGL's latest filing, from $2.0 million in the prior quarter.
  • Across five years, Receivables topped out at $10.8 million in Q3 2022 and bottomed at $62000.0 in Q4 2022.
  • Historically, Receivables has averaged $5.2 million across 5 years, with a median of $4.8 million in 2023.
  • On a YoY basis, Receivables climbed as much as 1268.27% in 2022 and fell as far as 99.53% in 2022.
  • Sol-Gel Technologies' Receivables stood at $62000.0 in 2022, then surged by 508.06% to $377000.0 in 2023, then jumped by 853.58% to $3.6 million in 2024, then slumped by 45.26% to $2.0 million in 2025, then plunged by 45.78% to $1.1 million in 2026.
  • Business Quant data shows SLGL's Receivables at $1.1 million in Q1 2026, $2.0 million in Q4 2025, and $9.8 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 2.13 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 6.57 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 1.93 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 160.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 1.06 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 912.74 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 215.33 Mn
10 Sol-Gel Technologies 194.01 Mn 146.08 Mn - 713,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 713,000.00
Mar 31, 2026 1.07 Mn
Dec 31, 2025 1.97 Mn
Sep 30, 2025 9.85 Mn
Jun 30, 2025 10.04 Mn
Mar 31, 2025 3.88 Mn
Dec 31, 2024 3.60 Mn
Sep 30, 2024 7.02 Mn
Jun 30, 2024 6.06 Mn
Mar 31, 2024 869,000.00
Dec 31, 2023 377,000.00
Jun 30, 2023 2.21 Mn
Mar 31, 2023 5.81 Mn
Dec 31, 2022 7.86 Mn
Sep 30, 2022 10.78 Mn
Jun 30, 2022 10.18 Mn
Mar 31, 2022 9.66 Mn
Dec 31, 2021 7.40 Mn
Sep 30, 2021 1.39 Mn
Jun 30, 2021 956,000.00